CS Diagnostics Corp. · OTC:CSDX
CS Diagnostics — Investor Presentation (October 2025)
21 slides from CS Diagnostics's investor presentation, October 2025
Slide 1: Investor Presentation
-CSCorp INVESTOR PRESENTATION
Slide 2: Values
VALUES OUR INNOVATION: We constantly seeking innovative solutions to improve therapy outcomes and enhance patient care globally EXCELLENCE : From product development to customer service, we ensure the highest standards of quality and efficacy GLOBAL IMPACT: We have close collaboration with healthcar
Slide 3: Our Market
MARKET OUR HOSPITALS CLINICS WHOLESALERS GOVERNMENTS, MOH‘s HOTELS, SCHOOLS, SPORT Our products are distributed through a robust network, ensuring availability and strict adherence to regulatory standards to ensure that our product meets the highest quality. 03
Slide 4: Our Market
DESINFECTION: MARKET OUR 150 MILLION $ HYDROGEL: 180 MILLION $ GERMANY DESINFECTION: 300 MILLION US DOLLARS HYDROGEL: USA TURKEY 150 MILLION US DOLLARS DESINFECTION: 10.7BILLION US DOLLARS HYDROGEL: 526 MILLION US DOLLARS EUROPE DESINFECTION: $3.01 BILLION HYDROGEL: 629 MILLION US DOLLARS SAUDI ARAB
Slide 5: Market Drivers
MARKET DRIVERS Rising Demand for Infection Control Adoption of Precision Medicine Increased awareness of hygiene & stringent Personalized healthcare & targeted therapies health regulations driving advanced, (e.g., hydrogel spacers in radiation oncology) long-lasting disinfection solutions. fueling m
Slide 6: Market Trends
MARKET TRENDS Expansion of Precision Oncology Solutions Shift Toward Eco-Friendly & Long-Lasting Increased use of hydrogel spacers in Disinfectants radiation therapy improving cancer High demand for sustainable, non- treatment accuracy. toxic, long-duration solutions reshaping the industry. Stronger
Slide 7: Partners
_ 07 S interpharm General Trading Co. LLC. Bay Square, Building 2, Office 8098816, Business Bay, Dubai, UAE Ref: 2024-2025-SPONSO-0255-MEDUSA Object: Agreement between PARIS SAINT-GERMAIN and CS Interpharm neral Trading Co. L.L.C. Dear Mohammad Salah Ahmad Alsayyed, Pursuant to the recent discussion
Slide 8: Partners
asanLuvd PARIS SAINT-GERMAIN +unique naming opportunity TOP BRAND EXPOSURE ) PLAYERS TRAINING SHORT MEDUSA STAFF TRAINING SHORT cscorp
Slide 9: Partners
PARIS SAINT-GERMAIN ips mening oppartanly MEDUSA ©. PITCHSIDE EXPOSURE TOP BRAND EXPOSURE © INTERVIEW & CONFERENCE ROOM Ee = -oENe=—omwe reg Kea ieee O CAMPUS VISIBILITY cscorp
Slide 10: Problem
PROBLEM HYDROGEL: Currently, there is no ready-to-use hydrogel solution that requires no certification or extensive training, posing significant hygiene risks and time constraints for medical professionals. Additionally, existing options like SpaceOAR Hydrogel are limited in application for the pros
Slide 11: Solutions
SOLUTIONS SOLUTIONFORHYDROGEL: Our hydrogel is ready-to-use, requires no additional Certification or training, and provides comprehensive coverage for various cancers, including prostate and breast cancer. SOLUTIONFORMEDUSA DISINFECTANT: Medusa offers a revolutionary solution with long- lasting prot
Slide 12: Our Products
PRODUCTS OUR • The surface disinfectant, to protect spaces from harmful bacteria, fungi, and viruses. • Proven Efficacy • Eco-Conscious • Sensitive Formula • Long-Lasting Protection lasts for 10 days In comparison to average products where the protection lasts less than 14 minutes Evaluated by Wrank
Slide 13: Our Products
PRODUCTS OUR HYDROGEL Experience the future of radiation therapy with our revolutionary hydrogel spacer. Designed to safeguard healthy tissue during cancer treatment, it sets a new standard in precision and efficiency. As the pinnacle of innovation in cancer care, it helps to maximize treatment accu
Slide 14: Why Investing With Us?
WHY INVESTING WITH US? • Global Reach • Proven Expertise: ◦ Sanochemia (Global Marketing & Sales): Increased diagnostic unit sales from €4M to €16M in 3 years. ◦ SPACEOAR: Launched in Europe, leading to $500M acquisition by Boston Scientific. ◦ Luminity: Saved 8,500 lives in 4 years through cardiolo
Slide 15: Risks
• ENVIRONMENTAL CONCERNS: STRICTER REGULATIONS AND DEMAND FOR ECO-FRIENDLY PRODUCTS. RISKS • REGULATORY CHANGES: FREQUENT UPDATES TO REGULATIONS IMPACT MARKET DYNAMICS. • MARKET SATURATION: HIGH COMPETITION AND RISK OF DECLINING PROFITABILITY. • ECONOMIC FACTORS: ECONOMIC DOWNTURNS REDUCE SPENDING O
Slide 16: How We Handle Risks
HOW WE HANDLE RISKS • Strong Branding: Emphasize German engineering • Product Differentiation: Highlight unique features and quality to build trust and recognition. like eco-friendly production and advanced technology. • Customer Loyalty: Focus on reliability and precision to maintain long-term cust
Slide 17: Use of Funds
USEOF FUNDS ALLOCATION OF FUNDSBASEDON DIFFERENTINVESTMENT LEVELS Production 24% 1,200,000 2,400,000 12,000,000 24,000,000 Laboratory R&D 12.5% 625,000 1,250,000 6,250,000 12,500,000 Regulatory & Registrations 15% 750,000 1,500,000 7,500,000 15,000,000 Marketing and Sales 23.5% 1,175,000 2,350,000 1
Slide 18: Milestones
MILESTONES F10 APPROVAL FOR FOR MEDUSA WITHIN FOR MEDUSA WITHIN FILE FORM 10 WITH CS-PROTECT EUROPE MARKETS MENA SECURITIES AND EXCHANGE HYDROGEL COMMISSION Reg D ISO 13485 APPROVAL FOR CONDUCT A REG D PPM TO OBTAINING APPLICATION TO MEDUSA RAISE THE NEEDED CAPITAL THE ISO 13485 UPLIFT FROM TO PRODU
Slide 19: The Ask
THE ASK Raising $10 million USD to unlock faster growth 2025 Q4 $10 MILLION FORECASTED 12 Months REVENUE $ 550K INVESTMENT REVENUE $50 MILLION 19
Slide 20: Leadership Team
LEADERSHIP TEAM Thomas Fahrhoefer Mohammad EsSayed Janel Luzana Group Chief Group Chairman Financial Officer Director Administration & Finance 25+ years experience in 20+ years experience in 11years CS Interpharm Director Healthcare Development Finance, Banking and and Distribution Corporate Managem
Slide 21: www.csdcorp.us
www.csdcorp.us info@csdcorp.us +1 307 395 7333
CS Diagnostics — Investor Presentation (October 2025) on 6ix